[
    [
        {
            "time": "",
            "original_text": "东吴证券维持康泰生物买入评级，2021半年报点评：业绩符合我们预期，下半年看核心产品放量",
            "features": {
                "keywords": [
                    "康泰生物",
                    "买入评级",
                    "2021半年报",
                    "业绩预期",
                    "核心产品",
                    "放量"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "东吴证券维持康泰生物买入评级，2021半年报点评：业绩符合我们预期，下半年看核心产品放量",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "医药行业：国内建议部分重点人群接种加强针",
            "features": {
                "keywords": [
                    "医药行业",
                    "加强针",
                    "重点人群",
                    "接种"
                ],
                "sentiment_score": 0.7,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药行业：国内建议部分重点人群接种加强针",
                "Correlation": 6,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
            "features": {
                "keywords": [
                    "医药",
                    "健康护理",
                    "智飞生物",
                    "新冠疫苗",
                    "III期数据",
                    "变异株",
                    "有效"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药与健康护理行业月报：智飞生物新冠疫苗III期数据优异 对变异株仍然有效",
                "Correlation": 7,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 6,
                "Market_Scope": 8,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]